Target therapy in elderly breast cancer patients

Abstract Substantial progress has been made in the management of breast cancer by targeting HER2 and VEGF pathways. Although the efficacy and safety of target therapy in breast cancer have been established, no specific phase III trial has addressed these issues in the elderly population and the only...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2012-09, Vol.83 (3), p.422-431
Main Authors: Carli, Paolo, Turchet, Elisa, Quitadamo, Daniela, Spada, Antonella, Miolo, Gianmaria, Lamaj, Elda, Spazzapan, Simon, Di Lauro, Vincenzo, Dolcetti, Riccardo, Veronesi, Andrea, Crivellari, Diana
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - pharmacology
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Bevacizumab
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Chemotherapy, Adjuvant
Clinical Trials as Topic
Elderly
Female
Gynecology. Andrology. Obstetrics
Hematologic and hematopoietic diseases
Hematology, Oncology and Palliative Medicine
Humans
Lapatinib
Mammary gland diseases
Medical sciences
Molecular Targeted Therapy
Neoplasm Metastasis
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Quinazolines - pharmacology
Quinazolines - therapeutic use
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Trastuzumab
Treatment Outcome
Tumors
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vascular Endothelial Growth Factor A - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Substantial progress has been made in the management of breast cancer by targeting HER2 and VEGF pathways. Although the efficacy and safety of target therapy in breast cancer have been established, no specific phase III trial has addressed these issues in the elderly population and the only data available derive from subanalyses or retrospective series. The aim of this review is to summarize the available evidence in this special population and to encourage further well designed studies in elderly breast cancer patients.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2011.12.004